lilly oral glp-1 is now pharma's top revenue company. It just got FDA approval for an GLP-1, but Wall Street isn't celebrating The Bioinformatics Behind Eli Lilly's
Description
Patients should work closely with their doctors to determine the best approach for their individual needs

Market Statistics Key Takeaways By type of GLP-1 agonist drugs, the long-acting GLP-1 agonist segment dominated in 2025
Changes reflect the placebo-subtracted effect
Diabetologia 56 , 965972 (2013)

Approval: 2005 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning
